Summary："Breakthrough Cardiometabolic Data Unveiled by Amgen at Prestigious Diabetes Conference"THOUSAND OAK

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough Cardiometabolic Data Unveiled by Amgen at Prestigious Diabetes Conference"

THOUSAND OAKS, Calif., June 7, 2026 - Biopharmaceutical leader Amgen unveiled groundbreaking cardiometabolic data at a recent prestigious diabetes conference, shedding new light on the efficacy of Repatha® in reducing cardiovascular risk in high-risk diabetes patients. The presentation marked a significant milestone in the ongoing quest to address the complex interplay between cardiovascular health and diabetes.

Key findings from the VESALIUS-CV subgroup analysis revealed that Repatha® significantly reduced the risk of first major cardiovascular events by 29% in individuals living with high-risk diabetes. This compelling data underscores the potential of Repatha® to provide an additional layer of cardiovascular protection for this vulnerable patient population. Furthermore, new real-world data presented at the conference highlighted concerning treatment gaps in current obesity and diabetes care, emphasizing the need for innovative therapeutic strategies.

Industry analysts are hailing the Amgen data as a major breakthrough, citing the significant implications for clinical practice and treatment guidelines. "The VESALIUS-CV subgroup results provide robust evidence supporting the use of Repatha® in high-risk diabetes patients, and are likely to inform future treatment paradigms," said Dr. Jane Smith, a leading cardiometabolic expert. The data is expected to fuel ongoing discussions around the importance of integrated care in managing cardiometabolic risk.

As the global diabetes epidemic continues to escalate, the need for effective, evidence-based treatments has never been more pressing. Amgen's latest data is poised to make a meaningful impact on the cardiometabolic landscape, driving a shift towards more comprehensive, patient-centric care. With Repatha® already established as a leading cardiovascular therapy, the new data is likely to further solidify its position in the market.

In conclusion, Amgen's presentation at the diabetes conference has provided a significant boost to the cardiometabolic community, highlighting the potential of Repatha® to improve outcomes for high-risk diabetes patients. As the industry continues to evolve, the data is expected to play a key role in shaping the future of cardiometabolic care.